Greece · Delayed Price · Currency is EUR Lavipharm Statistics
Total Valuation
Lavipharm has a market cap or net worth of EUR 267.10 million. The enterprise value is 304.75 million.
| Market Cap | 267.10M |
| Enterprise Value | 304.75M |
Important Dates
The last earnings date was Thursday, September 17, 2026.
| Earnings Date | Sep 17, 2026 |
| Ex-Dividend Date | Jul 20, 2026 |
Share Statistics
Lavipharm has 170.78 million shares outstanding. The number of shares has increased by 1.66% in one year.
| Current Share Class | 170.78M |
| Shares Outstanding | 170.78M |
| Shares Change (YoY) | +1.66% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 0.52% |
| Float | n/a |
Valuation Ratios
The trailing PE ratio is 47.66.
| PE Ratio | 47.66 |
| Forward PE | n/a |
| PS Ratio | 3.80 |
| PB Ratio | 4.74 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 37.47 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 53.07 |
| EV / Sales | 4.33 |
| EV / EBITDA | 21.66 |
| EV / EBIT | 34.21 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.22, with a Debt / Equity ratio of 0.73.
| Current Ratio | 1.22 |
| Quick Ratio | 0.64 |
| Debt / Equity | 0.73 |
| Debt / EBITDA | 2.93 |
| Debt / FCF | -8.26 |
| Interest Coverage | 4.90 |
Financial Efficiency
Return on equity (ROE) is 10.22% and return on invested capital (ROIC) is 7.41%.
| Return on Equity (ROE) | 10.22% |
| Return on Assets (ROA) | 4.18% |
| Return on Invested Capital (ROIC) | 7.41% |
| Return on Capital Employed (ROCE) | 9.27% |
| Weighted Average Cost of Capital (WACC) | 8.88% |
| Revenue Per Employee | 246,719 |
| Profits Per Employee | 20,151 |
| Employee Count | 285 |
| Asset Turnover | 0.53 |
| Inventory Turnover | 1.59 |
Taxes
In the past 12 months, Lavipharm has paid 2.05 million in taxes.
| Income Tax | 2.05M |
| Effective Tax Rate | 26.30% |
Stock Price Statistics
The stock price has increased by +85.09% in the last 52 weeks. The beta is 1.00, so Lavipharm's price volatility has been similar to the market average.
| Beta (5Y) | 1.00 |
| 52-Week Price Change | +85.09% |
| 50-Day Moving Average | 1.57 |
| 200-Day Moving Average | 1.37 |
| Relative Strength Index (RSI) | 43.87 |
| Average Volume (20 Days) | 118,014 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Lavipharm had revenue of EUR 70.32 million and earned 5.74 million in profits. Earnings per share was 0.03.
| Revenue | 70.32M |
| Gross Profit | 33.15M |
| Operating Income | 8.91M |
| Pretax Income | 7.80M |
| Net Income | 5.74M |
| EBITDA | 13.27M |
| EBIT | 8.91M |
| Earnings Per Share (EPS) | 0.03 |
Balance Sheet
The company has 3.62 million in cash and 41.28 million in debt, with a net cash position of -37.66 million or -0.22 per share.
| Cash & Cash Equivalents | 3.62M |
| Total Debt | 41.28M |
| Net Cash | -37.66M |
| Net Cash Per Share | -0.22 |
| Equity (Book Value) | 56.36M |
| Book Value Per Share | n/a |
| Working Capital | 9.71M |
Cash Flow
In the last 12 months, operating cash flow was 7.13 million and capital expenditures -12.13 million, giving a free cash flow of -5.00 million.
| Operating Cash Flow | 7.13M |
| Capital Expenditures | -12.13M |
| Depreciation & Amortization | 4.36M |
| Net Borrowing | 8.70M |
| Free Cash Flow | -5.00M |
| FCF Per Share | -0.03 |
Margins
Gross margin is 47.14%, with operating and profit margins of 12.67% and 8.17%.
| Gross Margin | 47.14% |
| Operating Margin | 12.67% |
| Pretax Margin | 11.09% |
| Profit Margin | 8.17% |
| EBITDA Margin | 18.87% |
| EBIT Margin | 12.67% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 0.02, which amounts to a dividend yield of 1.27%.
| Dividend Per Share | 0.02 |
| Dividend Yield | 1.27% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 58.87% |
| FCF Payout Ratio | n/a |
| Buyback Yield | -1.66% |
| Shareholder Yield | -0.39% |
| Earnings Yield | 2.15% |
| FCF Yield | -1.87% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on August 1, 2022. It was a reverse split with a ratio of 0.3333333333.
| Last Split Date | Aug 1, 2022 |
| Split Type | Reverse |
| Split Ratio | 0.3333333333 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 6 |